據外媒2014年7月23日消息,布魯克表示,它不相信其化學與應用市場部門(CAM)可以在未來兩年內實現“可接受的財務表現”,它計劃出售和或重組部分CAM業務,由此預期裁員200到250人。
在提交給美國證券交易委員會(SEC)的一份文件中,布魯克說,重組計劃將導致每年收入減少5000-7000萬美元,重組完成后,每年利潤預計可以增加1500-2000萬元美元。
重組CAM部門的決定已由布魯克董事會于7月18日批準,公司認為保留此業務已不再有意義。2010年,布魯克在收購了瓦里安部分業務后成立了CAM部門,并且從一開始,CAM就是布魯克財務的一個權重。在最近的一次投資者會議上,該公司負責人表示,布魯克將改革該部門。
在今天提交給SEC的文件中,布魯克列出重組CAM計劃的細節。它打算剝離或出售CAM的氣相產品線及相關服務,包括氣相系統和單四極桿氣質系統。布魯克說,至少一些資產的潛在銷售正在討論。
此外,布魯克擬出售或重組CAM的電感耦合等離子體質譜產品線(ICP-MS)及相關服務,并正在對這些資產的潛在銷售進行討論。但是,布魯克將保留CAM的三重四極桿氣質/液質產品線及相關服務,布魯克認為這部分業務在制藥、臨床和生命科學研究市場有增長的機會。
布魯克將從第三季度開始實施CAM重組計劃,重組預計到2015年6月30日前完成。
布魯克預計在2014下半年及2015年上半年CAM重組及其他一次性費用在3500-4000萬美元之間。布魯克還說,任何CAM相關業務出售的預期收益當前無法計算。
2013年,CAM部門的收入約1億美元。消息公布后,布魯克股票上漲了近3%,股價24.09美元。
附:布魯克公司關于此事告客戶信
Important customer information about ICP-MS, GC and GC-MS products
Dear Valued Bruker Customer,
After very careful analysis of our served markets and product portfolio, Bruker today announced the decision to reduce its Chemical & Applied Markets (CAM) Division product portfolio. Unfortunately, this decision became inevitable as CAM had generated significant losses for the last 4 years, and with its broad product and market scope there was no way to reach acceptable financial performance for CAM in the foreseeable future.
As a result of this decision, effective immediately, Bruker will stop selling its stand-alone GC systems and its single-quadrupole (SQ) GC-SQ mass spectrometry systems. Bruker will deliver and install our existing GC and GC-SQ order backlog, and we will continue to provide service and support for these products and there will be no change in customer service.
Bruker has also announced that it is seeking strategic buyers for its GC service business and separately for our ICP-MS business. If these businesses are divested to other global, analytical instrument companies, then further communications will be made to all customers.
Bruker will continue to develop, manufacture, sell and service our strategically important and successful EVOQ LC-MS and SCION GC-MS triple-quadruple (TQ) products as part of our Bruker Daltonics mass spectrometry product portfolio.
So what will this all mean to you?
We will continue to honor our service commitments for the GC and GC-SQ systems. Our GC systems service may be transferred to a potential other major analytical systems company before the end of 2014. We will retain GC-SQ service at Bruker.
We will deliver and install our GC and GC-SQ backlog during the second half of 2014, and we accept last-buy orders for GC and GC-SQ during the third quarter of 2014.
We will continue to invest vigorously in TQ-MS systems and their applied market applications. Our award-winning SCION GC-TQ and EVOQ LC-TQ systems will be retained by Bruker for sale by our commercial team and our approved distributors.
We will keep selling and supporting ICP-MS systems while we transition this business to a potential buyer. We expect to transfer our ICP-MS business to a global, high-quality analytical instruments company with a broader trace elemental analysis portfolio in the next few months.
This was a very difficult decision for Bruker and we will work hard with our valued customers to ensure minimization of any inconvenience caused by this decision and announcement.
Sincerely,
Elmar Illek
Senior Vice President
Bruker Daltonics Commercial Operations
——EMILIE與MIROMGA的技術特點及多領域應用從空氣中的超細氣溶膠顆粒、納米塑料,到少量蛋白質樣品和氣體中的痕量組分,越來越多的研究需要在樣品量有限或濃度變化微弱時,獲得可靠的化學信息。紅外光......
在近日舉行的布魯克2026年第二季度業績電話會議上,公司總裁兼首席執行官FrankLaukien宣布了一項重大戰略調整:"自7月1日起,布魯克已采用全新的運營結構,將BioSpin、Dalt......
——解碼分子高級結構,精研多組學分析由布魯克(北京)科技有限公司主辦、上海梧桐島生命科學研究院協辦的布魯克質譜新技術前瞻論壇于2026年5月15日在上海生物醫藥前沿產業創新中心成功舉辦。論壇聚焦“解碼......
——ASMS2026布魯克高層訪談2026年6月初,第74屆美國質譜年會(ASMS2026)在圣迭戈成功舉辦,年會向來自全球各地的質譜專家、廠商、客戶及媒體朋友展示了全球前沿質譜技術與科研成果。展會期......
當地時間2026年6月,第74屆美國質譜年會(ASMS2026)在圣地亞哥順利舉辦,這場行業盛會匯聚了全球前沿的質譜技術與科研成果。展會期間,布魯克聚焦4D多組學與功能蛋白質組學2.0,集中展示多款全......
2026年5月15日上海——由布魯克(北京)科技有限公司主辦、上海梧桐島生命科學研究院協辦的布魯克質譜新技術前瞻論壇,以“質譜無界,創新無限”為主題,采用線上線下相結合的方式,在上海生物醫藥前沿產業創......
近日,中國科學院寧波材料技術與工程研究所多個儀器設備采購項目中標結果陸續公布,涉及光電材料、金屬材料、高分子材料等多個研究方向。本次中標的核心儀器包括:掃描電子顯微鏡、400MHz超導核磁共振波譜儀、......
布魯克公司(納斯達克股票代碼:BRKR)近日公布了截至2025年12月31日的第四季度及全年財務業績。2025財年營收為34.4億美元,同比增長約2%,有機收入下降約4%;凈利潤虧損860萬美元,與2......
2026年1月12日,在第44屆摩根大通醫療健康年會上,布魯克董事長、首席執行官兼總裁FrankLaukien攜管理團隊出席并發表演講。演講中,Laukien多次強調2025年是布魯克極具挑戰的一年,......
2026年1月8日瑞士圖恩,布魯克公司(BrukerCorporation,Nasdaq:BRKR)宣布收購TOFWERK公司60%的股權。本次交易完成后,布魯克對該公司持股比例達到100%,實現全面......